Intravitreal anti-vascular endothelial growth factor (VEGF) drugs have revolutionized the
treatment of neovascular age-related macular degeneration (NVAMD). However, many …

Today, the average life expectancy in developed nations is over 80 years and climbing. And
yet, the quality of life during those additional years is often significantly diminished by the …

Age-related macular degeneration (AMD) is the most frequent cause of irreversible
blindness in the elderly in developed countries. Our previous studies implicated activation of …

Age-related macular degeneration (AMD), the leading cause of blindness in the elderly, is a
complex disease to study because of the potential role of demographic, environmental, and …

Biomarkers can help unravel mechanisms of disease and identify new targets for therapy.
They can also be useful in clinical practice for monitoring disease progression, evaluation of …

Although age-related macular degeneration (AMD) is not a classic inflammatory disease like
uveitis, inflammation has been found to have an important role in disease pathogenesis and …

Purpose: To evaluate the efficacy and safety of triple therapy with verteporfin photodynamic
therapy (PDT), dexamethasone, and bevacizumab in choroidal neovascularization (CNV) …

Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly.
The cause of AMD is complex and many risk factors have been implicated including age …

Autoantibody production is associated with a variety of ocular disorders, including
autoimmune retinopathy (AIR) and age-related macular degeneration (AMD). A breakdown …

Age‐related macular degeneration (AMD) is the leading cause of vision loss in the elderly
throughout the industrialized world. Its most prominent pathologic features are lesions …